- Home
- GGAL vs ROIV Comparison
GGAL vs ROIV Comparison
Compare GGAL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGAL
- ROIV
- Stock Information
- Founded
- GGAL 1905
- ROIV 2014
- Country
- GGAL Argentina
- ROIV United Kingdom
- Employees
- GGAL 12440
- ROIV N/A
- Industry
- GGAL Commercial Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- GGAL Finance
- ROIV Health Care
- Exchange
- GGAL Nasdaq
- ROIV Nasdaq
- Market Cap
- GGAL 9.4B
- ROIV 8.4B
- IPO Year
- GGAL N/A
- ROIV N/A
- Fundamental
- Price
- GGAL $62.71
- ROIV $10.67
- Analyst Decision
- GGAL Strong Buy
- ROIV Buy
- Analyst Count
- GGAL 4
- ROIV 4
- Target Price
- GGAL $59.00
- ROIV $17.50
- AVG Volume (30 Days)
- GGAL 1.1M
- ROIV 5.9M
- Earning Date
- GGAL 01-01-0001
- ROIV 05-29-2025
- Dividend Yield
- GGAL 3.80%
- ROIV N/A
- EPS Growth
- GGAL 120.03
- ROIV N/A
- EPS
- GGAL 1.06
- ROIV N/A
- Revenue
- GGAL $6,697,505,438.00
- ROIV $122,585,000.00
- Revenue This Year
- GGAL $11.73
- ROIV N/A
- Revenue Next Year
- GGAL N/A
- ROIV N/A
- P/E Ratio
- GGAL $6.63
- ROIV N/A
- Revenue Growth
- GGAL N/A
- ROIV 140.04
- 52 Week Low
- GGAL $23.53
- ROIV $8.73
- 52 Week High
- GGAL $74.00
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- GGAL 59.78
- ROIV 47.82
- Support Level
- GGAL $57.11
- ROIV $10.58
- Resistance Level
- GGAL $63.69
- ROIV $11.77
- Average True Range (ATR)
- GGAL 2.34
- ROIV 0.34
- MACD
- GGAL 0.16
- ROIV -0.07
- Stochastic Oscillator
- GGAL 74.71
- ROIV 7.56
About GGAL Grupo Financiero Galicia S.A.
Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.